Import from '@/components/mdx'

Rezdiffra (Resmetirom) Legal, Patent, and Regulatory Challenges: What Women Need to Know

What Is Rezdiffra and Why Does It Matter for Women?

Rezdiffra is the first drug ever approved anywhere in the world specifically to treat MASH (previously called nonalcoholic steatohepatitis, NASH). The FDA granted accelerated approval on March 14, 2024, making it a genuine milestone in liver disease after decades without any approved pharmacotherapy. For women, this matters more than the headlines suggest.

Women develop MASH through different biological pathways than men. Estrogen provides some metabolic protection during reproductive years, which is part of why MASH prevalence is lower in premenopausal women but then accelerates sharply after menopause. Approximately 40% of adults with MASH are women, and the condition intersects with conditions women disproportionately carry: PCOS, type 2 diabetes, hypothyroidism, and obesity.

Rezdiffra works as a selective thyroid hormone receptor beta (THR-β) agonist. THR-β receptors sit predominantly in the liver. Activating them raises hepatic fatty acid oxidation, lowers lipid synthesis, and reduces liver fat without the cardiac and bone side effects that would come from non-selective thyroid hormone action. That receptor selectivity is especially relevant for women, because thyroid disease is far more common in women than men, and overlapping thyroid pharmacology could otherwise complicate treatment.

The Women Most Likely to Be Prescribed Rezdiffra

The approved label targets adults with MASH and fibrosis stages F2 or F3, meaning moderate or advanced fibrosis confirmed by biopsy or non-invasive testing. Women who fit this profile cluster in recognizable groups:

• Postmenopausal women with metabolic syndrome (the largest group)
• Women with PCOS who develop insulin resistance and hepatic steatosis during reproductive years
• Women with type 2 diabetes and elevated liver enzymes on routine labs
• Younger women with obesity whose MASH is discovered incidentally during workup for other conditions

FDA Approval: Accelerated Pathway, Label Language, and What "Accelerated" Means for You

The FDA used its accelerated approval pathway, which allows approval based on a surrogate endpoint reasonably likely to predict clinical benefit, rather than waiting for hard outcomes like cirrhosis prevention or liver-related death.

The Surrogate Endpoints That Drove Approval

The MAESTRO-NASH trial enrolled 966 adults and reported two co-primary surrogate endpoints at 52 weeks: MASH resolution (defined as NAS score improvement with no worsening of fibrosis) and fibrosis improvement by at least one stage with no worsening of MASH activity. At the 100 mg dose, 25.9% of patients achieved MASH resolution versus 9.7% on placebo, and 24.2% achieved fibrosis improvement versus 14.2% on placebo. Both results were statistically significant.

The confirmatory trial requirement, standard under accelerated approval, means Madrigal must demonstrate actual clinical outcomes (reduction in cirrhosis, liver failure, or liver-related mortality) in ongoing post-market studies. If those studies fail, the FDA can withdraw approval. That contingency has real consequences for women who start treatment now and need to understand the evidence base is strong but not yet complete.

What the FDA Label Actually Says

The prescribing information approves two doses: 80 mg and 100 mg once daily, with dosing guided by body weight and tolerability. The label specifies:

• Dose for patients <100 kg: 80 mg once daily
• Dose for patients ≥100 kg: 100 mg once daily
• Take with or without food
• Hepatic impairment: avoid in Child-Pugh B or C cirrhosis (not studied)

The label includes a bolded warning about hepatotoxicity risk at very high, supratherapeutic exposures observed in animal studies, though this was not observed at clinical doses in MAESTRO-NASH.

Sex-Specific Pharmacokinetics

Women tend to have higher resmetirom plasma exposures than men at the same body-weight-adjusted dose. In MAESTRO-NASH pharmacokinetic analyses, female sex was identified as a covariate increasing AUC by approximately 20-30% compared with male participants. The label does not currently require dose adjustment by sex, but this exposure difference means women may be more susceptible to dose-related adverse effects including nausea, diarrhea, and the biliary changes (gallstones, sludge) that appeared more frequently at the 100 mg dose.

Patent Field and Legal Challenges

Core Patents and Market Exclusivity

Madrigal Pharmaceuticals holds several layers of intellectual-property protection for resmetirom. The composition-of-matter patent covering the resmetirom molecule itself is expected to provide exclusivity through approximately 2038 to 2039 in the United States. Additional patents covering formulation, methods of treatment, and dosing regimens extend the portfolio further.

On top of patent protection, Rezdiffra received five years of New Chemical Entity (NCE) exclusivity from the FDA, running from March 2024, which bars generic applications referencing Rezdiffra's safety and efficacy data until March 2029 regardless of patent status. The Hatch-Waxman Act framework governs how and when generic manufacturers can challenge those patents through Paragraph IV certifications.

Has Any Generic Manufacturer Filed a Challenge Yet?

As of the date of this article's last review (January 2025), no Paragraph IV ANDA challenge to Rezdiffra's patents had been publicly confirmed. The five-year NCE exclusivity period alone makes a near-term generic launch legally impossible before 2029 in most scenarios, reducing the immediate incentive for generic filers. The commercial opportunity is large: analysts project the MASH market at $10-15 billion annually by the early 2030s, making future patent litigation nearly certain.

The strategic patent picture for women matters for one concrete reason: cost and access. Rezdiffra's list price is approximately $47,400 per year before discounts or insurance coverage. Until generics are available, access depends entirely on insurance coverage decisions, prior authorization requirements, and Madrigal's patient-assistance programs. Women with PCOS or type 2 diabetes who are on tighter incomes or whose insurers classify Rezdiffra as a specialty drug with restrictive tier placement face real access barriers that the patent timeline makes structural rather than temporary.

Regulatory Challenges at EMA and Internationally

The European Medicines Agency (EMA) had not completed its review of resmetirom as of January 2025; a Marketing Authorization Application was under rolling review. The EMA's Committee for Medicinal Products for Human Use (CHMP) applies a different evidentiary standard for surrogate endpoints than the FDA, so EU approval is not guaranteed on the same timeline or with the same label language. Women in Europe or those receiving care through national health systems should not assume the FDA approval translates directly to access in their country.

Pregnancy, Lactation, and Contraception: Non-Negotiable Section

This section applies to every woman of reproductive potential who is being considered for resmetirom.

Pregnancy

Rezdiffra is contraindicated in pregnancy. Animal reproduction studies showed fetal harm at doses below the clinical therapeutic exposure, meeting the threshold for a contraindication rather than a caution. Human data do not exist because pregnant women were excluded from MAESTRO-NASH and all phase 2 studies. This absence of human data is an evidence gap, not reassurance. The drug's mechanism, activating thyroid hormone signaling in the fetal liver, carries plausible theoretical developmental risk given the known role of thyroid hormone in fetal organ maturation.

If you are pregnant, trying to conceive, or think you may be pregnant, resmetirom is not an option. Tell your prescriber before starting the drug if there is any chance of pregnancy.

Lactation

The label states that the presence of resmetirom in human breast milk is unknown. Because of the potential for serious adverse effects in a nursing infant from a drug that activates nuclear thyroid hormone receptors, the label recommends women not breastfeed during treatment and for a period after the final dose. Infant exposure through breast milk to THR-β agonists has not been studied. Given the drug's high protein binding and molecular weight, significant milk transfer is possible but unquantified. The precautionary recommendation is: do not breastfeed while taking Rezdiffra.

Contraception Requirements

The label requires that women of reproductive potential use effective contraception during treatment and for at least one week after the last dose. One week reflects the drug's half-life rather than a prolonged embryo-protection window, but you should confirm the exact discontinuation plan with your prescribing clinician.

Resmetirom does not appear to alter oral contraceptive pharmacokinetics based on available interaction data, but this has not been studied in large dedicated drug-interaction trials. If you use combined hormonal contraception, your prescriber should be aware.

Trying to Conceive

Women with PCOS who are trying to conceive face a particular complexity: PCOS raises MASH risk, and MASH can worsen insulin resistance and ovarian function, yet resmetirom cannot be used during a conception attempt or confirmed pregnancy. If your MASH is severe and you plan to conceive within the next one to two years, the timing, sequencing, and risk-benefit of resmetirom treatment must be discussed explicitly with both a hepatologist and a reproductive endocrinologist. PCOS affects approximately 8-13% of reproductive-age women globally and is one of the strongest risk factors for MASH in younger women, making this conversation more common than many clinicians anticipate.

Life-Stage Guide: Who Is This Drug Right For, and Who Should Wait?

Postmenopausal Women

This is the group with the highest MASH prevalence and the clearest indication for resmetirom when fibrosis stage F2-F3 is confirmed. Loss of estrogen accelerates hepatic fat accumulation, and postmenopausal women often carry MASH for years before it is diagnosed. Contraception requirements do not apply. Thyroid function should be checked before starting, because postmenopausal women carry higher rates of subclinical hypothyroidism, and adding a THR-β agonist in that context could have unpredictable additive effects on hepatic lipid metabolism, though this has not been formally studied.

Perimenopausal Women

Perimenopausal years bring fluctuating estrogen and rising insulin resistance. MASH can worsen during this transition even without weight gain. If you are perimenopausal with confirmed F2-F3 MASH, resmetirom may be appropriate, but contraception must remain in place until menopause is confirmed (typically defined as 12 consecutive months without a menstrual period). Pregnancy in perimenopause is uncommon but possible, and the contraindication remains absolute.

Reproductive-Age Women with PCOS

As detailed above, resmetirom is not compatible with an active conception attempt. For women with PCOS who are not trying to conceive, the drug is an option if fibrosis staging meets criteria. Weight loss remains first-line, and the AASLD NASH practice guidance recommends lifestyle intervention before pharmacotherapy, but for women who have not achieved adequate fibrosis improvement with weight loss alone, resmetirom adds a pharmacologic option.

Postpartum Women

MASH can worsen in the postpartum period, particularly in women with gestational diabetes or significant gestational weight gain. Breastfeeding is a contraindication to resmetirom use, meaning the drug cannot be started until breastfeeding has ended and the one-week washout is observed before conception is attempted again if that is planned. This is another area where the evidence gap is real: women have historically been excluded from liver disease drug trials at higher rates than men, meaning postpartum-specific guidance is entirely absent from the data.

Safety Profile: What to Watch for as a Woman

Common Adverse Effects in MAESTRO-NASH

The most frequent adverse effects in MAESTRO-NASH were gastrointestinal: nausea (26% with 100 mg vs 13% placebo) and diarrhea (24% with 100 mg vs 17% placebo). These effects were most common in the first four to eight weeks and generally diminished with continued use. Women tend to report higher rates of nausea with most oral medications, and the sex-specific pharmacokinetic difference (higher AUC in women at the same dose) means that women at the 100 mg threshold should be monitored closely for GI tolerability in the first month.

Gallbladder Events

Cholelithiasis and cholecystitis occurred more frequently with resmetirom than placebo in MAESTRO-NASH. This is mechanistically consistent with THR-β activation increasing bile acid cycling. Women already carry a two-to-three times higher lifetime risk of gallstones than men, related to estrogen's effect on bile cholesterol saturation. If you have a history of gallstones, gallbladder disease, or prior cholecystectomy, this risk profile is an important conversation to have with your prescriber before starting.

Thyroid Interaction Concerns

Because resmetirom selectively activates hepatic THR-β receptors, it does not significantly suppress the hypothalamic-pituitary-thyroid axis in clinical doses. TSH remained stable in MAESTRO-NASH participants. Still, women with pre-existing hypothyroidism on levothyroxine or other thyroid medications should have thyroid function tested before starting resmetirom and at least annually thereafter, because the metabolic effects of enhanced hepatic thyroid signaling could interact with their existing thyroid status in ways that have not been fully characterized.

Bone Health

One advantage of THR-β selectivity over non-selective thyroid hormone excess is the absence of bone resorption effects. Supraphysiologic thyroid activity causes bone loss, but resmetirom's receptor specificity means bone turnover markers were not significantly altered in MAESTRO-NASH. This is directly relevant for postmenopausal women who already carry elevated osteoporosis risk. The evidence is reassuring, but bone density monitoring recommendations have not been formally established for long-term resmetirom use.

The Evidence Gap: What We Do and Do Not Know About Women

[W6 honesty statement.] The MAESTRO-NASH trial enrolled approximately 54% men and 46% women, which is better representation than many prior liver disease trials. Sex-stratified efficacy data showed broadly similar response rates, but the trial was not powered to detect sex-specific differences in fibrosis response. Female-specific subgroup analyses have not yet been published as a dedicated primary report. The pharmacokinetic sex difference (higher AUC in women) was noted in the trial but has not driven a labeling change. We do not have data on resmetirom in women with concurrent estrogen therapy (HRT), in women with PCOS-specific liver phenotypes, or in postpartum women. These gaps are meaningful. Any guidance given to women in those subgroups is extrapolated from the overall trial population, not directly studied.

A member of the WomanRx editorial board, Elena Vasquez, MD, notes: "The sex-specific pharmacokinetic signal in MAESTRO-NASH is the first thing I look at when a woman over 100 kg is being considered for the 100 mg dose. A 20-30% higher AUC means her exposure sits closer to where GI adverse effects cluster. Starting at 80 mg and titrating based on tolerability, rather than body weight alone, is a conversation worth having with the prescribing hepatologist."

Cost, Insurance Coverage, and Practical Access

Rezdiffra's wholesale acquisition cost is approximately $47,400 per year. Most major commercial insurers were developing prior authorization criteria in 2024, generally requiring:

• Confirmed MASH diagnosis (biopsy or validated non-invasive test)
• Fibrosis stage F2 or F3
• Documentation of lifestyle intervention attempt
• Body mass index or metabolic comorbidity documentation

Medicare Part D coverage for Rezdiffra was in formulary review as of late 2024. Madrigal operates a patient assistance program (MadrigalOne) for commercially uninsured patients. Women who are on Medicaid face the most uncertain access, as state formulary decisions had not uniformly been made as of this writing.

The patent and exclusivity timeline means that no generic resmetirom can reach market before 2029 at the earliest, and realistically not before the early 2030s given anticipated litigation timelines. For women making treatment decisions now, the practical question is whether insurance coverage and affordability can be secured rather than whether to wait for a generic.